Aivo Biosciences, Inc.
- Biotech or pharma, therapeutic R&D
Aivo Biosciences is a preclinical-stage biotech based in San Diego (inc. in Nov 2024), developing optimized small molecules for neuropsychiatric and neurodegenerative diseases. Our lead muscarinic receptor small molecule allosteric (non-PAM) agonist is developed initially for schizophrenia and dementia-related psychosis. The lead candidate, now being prepared for IND-enabling GLP tox, is highly potent (EC50 ~1 nM) and selective, with excellent drug-like properties, incl. optimized brain penetration and half-life compatible with once-daily dosing.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}